NeuroOne gains from Zimmer license and OneRF sales, raises cash but remains unprofitable

NeuroOne Medical Technologies Corporation (NMTC) - OTCBB

Quick summary - what's happening inside
NeuroOne is transitioning from development into commercial sales. License revenue from a Zimmer distribution agreement ($3.0M recognized in the nine months) plus strong OneRF product sales drove large revenue and margin improvement in FY2025 YTD. Management reduced operating burn, completed a big equity raise in April 2025 and finished the period with a healthier cash balance - but the company remains loss-making, heavily dependent on one distributor/customer and materially diluted versus prior year.

Key points & statistics
- Cash and cash equivalents (June 30, 2025): $8,039,683 (up from $1,460,042 at Sept. 30, 2024).
- Total assets: $10,819,481; Total liabilities: $2,642,028; Total stockholders' equity: $8,177,453 (June 30, 2025).
- Product revenue - three months ended June 30, 2025: $1,696,050 vs $825,776 (Q3 2024).
- Product revenue - nine months ended June 30, 2025: $6,356,767 vs $3,180,719 (YTD 2024).
- License revenue (nine months ended June 30, 2025): $3,000,000 (Zimmer RF distribution license recognized at point in time).
- Product gross profit - nine months 2025: $3,612,785 (56.8% gross margin) vs $938,605 (29.5% GM) in 2024.
- Net loss - three months ended June 30, 2025: $(1,500,868); three months 2024: $(2,767,525).
- Net loss - nine months ended June 30, 2025: $(1,986,153) vs $(8,967,515) in 2024 (large improvement).
- Net loss per share - three months: $(0.03) vs $(0.10); nine months: $(0.05) vs $(0.35).
- Shares outstanding (Aug 12, 2025): 49,999,519. Shares issued June 30, 2025: 49,824,780 (up from 30,816,499 Sept. 30, 2024).
- Warrant liability (June 30, 2025): $1,040,894 (down from $2,140,315 Sept. 30, 2024); warrants outstanding: 7,045,875.
- Stock options outstanding: 6,131,448; RSUs outstanding: 848,468. Unrecognized stock-based comp: $3,227,785 (weighted average recognition period 3.7 years).
- Cash from financing (nine months 2025): $7,962,376 (net proceeds from April 2025 financing ≈ $8,239,283; ATM proceeds included $414,037).

Positive aspects of the income statement
- Revenue growth: Product revenue roughly doubled YTD (from $3.18M to $6.36M).
- License cash-in: $3.0M license payment from Zimmer recognized in the period - non-recurring but materially improves results and liquidity.
- Gross margin expansion: Product gross margin improved to 56.8% (nine months), driven by higher‑margin OneRF sales under the Zimmer Amendment.
- Lower operating burn: Loss from operations narrowed substantially (nine months 2025: $(2.86M) vs 2024: $(9.07M)), helped by reduced SG&A and R&D and the license recognition.
- Reduced warrant liability swing helped earnings: fair-value decrease of ~$1.1M was recognized as income in nine months 2025.

Negative aspects of the income statement / risks
- Still unprofitable: Net loss remains $(1.99M) YTD; accumulated deficit $76,990,566 as of June 30, 2025.
- Customer concentration: One customer accounted for 100% of product revenue in the quarter and 96% for the nine months - single-customer risk is acute.
- Heavy dilution: Share count jumped from ~30.8M to ~49.8M in less than a year after equity financings; warrants/options add further potential dilution.
- Non-recurring nature of some gains: $3.0M license revenue and a significant fair-value gain on warrant liability are not sustainable operating revenue sources.
- Financing costs and issuance expenses are material (April 2025 financing issuance costs ~$960,717 plus ATM and PIPE costs), reducing net proceeds.
- Dependency on Zimmer for commercialization and revenue recognition - termination or underperformance by Zimmer would materially affect revenue.
- Supplier concentration: key manufacturing concentrated with single contract manufacturers - operational risk for product supply and cost control.

Operational & liquidity takeaways
- Management reduced cash burn and rebuilt the cash balance via the April 2025 equity offering (net ≈ $8.24M). They state cash and revenue should fund operations for at least 12 months from issuance date, but the company notes past substantial doubt from auditors and remains dependent on future capital or commercial traction.
- The business is moving to product-led revenue (OneRF) but remains early stage: commercial scale, diversification of customers, and margin sustainability are the next execution milestones.

Bottom line: NeuroOne (OTCBB: NMTC) shows clear top-line progress and margin improvement driven by OneRF sales and the Zimmer license payment, and successfully refreshed liquidity with an April 2025 equity raise. However, it remains loss-making, highly concentrated (customer and supplier), meaningfully diluted, and dependent on continued execution from Zimmer and future financing or sustained product sales to reach profitability.